作者
Fokkens, W. J.,Lund, V. J.,Hopkins, C.,Hellings, P. W.,Kern, R.,Reitsma, S.,Toppila-Salmi, S.,Bernal-Sprekelsen, M.,Mullol, J.,Alobid, I.,Terezinha Anselmo-Lima, W.,Bachert, C.,Baroody, F.,von Buchwald, C.,Cervin, A.,Cohen, N.,Constantinidis, J.,De Gabory, L.,Desrosiers, M.,Diamant, Z.
摘要
EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. no immunosuppressants IV D no nasal saline irrigation Ib, no data in single use D yes for symptomatic relief topical antibiotics no data D no anti-IL-5 no data D unclear phytotherapy no data D no decongestant topical / oral no data in single use D no mucolytics no data D no oral antihistamine in allergic patients no data D no antimycotics -topical Ia (-) ** A(-) no antimycotics -systemic Ib (-)# A(-) $ no anti leukotrienes Ib (-) A(-) no anti-IgE Ib (-) A(-) no * Some of these studies also included patients with CRS with nasal polyps. % short term antibiotics shows one positive and one negative study. Therefore recommendation C. oral antibiotic short term <4 weeks Ib(-) # A(-)* no intravenous antibiotics III(-) ## C(-) ** no # Ib (-): Ib study with a negative outcome.